Another attractive application in the BC field concerns the use of FAPi-PET as a guide for the selection of patients for radio-ligand therapy (RLT) with FAP-specific inhibitors, using high-energy β-emitters, such as Lutetium-177. Here, FAP is linked to breast cancer.